FAM118A

Across TCGA pan-cancer cohorts, FAM118A mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FAM118A data layer compared with 22 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher FAM118A mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated FAM118A expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC, LSCC, and GBM are the cancer types where FAM118A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	II,III,IV	0.751	0.352	<.001	34	view →
LSCC	DFS	Quartile	II,III,IV	0.426	0.933	.003	25	view →
GBM	OS	Median	All	0.334	0.661	.029	5	view →
HNSC	OS	Median	III,IV	0.945	1.000	.037	1	view →
CCRCC	OS	Quartile	II,III,IV	0.364	0.773	.023	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

FAM118A–PDAC (OS)

Open the PDAC breakdown →